Free Trial
NASDAQ:TNGX

Tango Therapeutics (TNGX) Stock Price, News & Analysis

$7.27
+0.35 (+5.06%)
(As of 11:20 AM ET)
Today's Range
$7.11
$7.36
50-Day Range
$6.66
$7.91
52-Week Range
$2.88
$13.03
Volume
102,705 shs
Average Volume
613,597 shs
Market Capitalization
$776.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.17

Tango Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.14 Rating Score
Upside/​Downside
104.7% Upside
$14.17 Price Target
Short Interest
Bearish
12.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.82mentions of Tango Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$1.47 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.31) to ($1.35) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.41 out of 5 stars

Medical Sector

419th out of 905 stocks

Pharmaceutical Preparations Industry

196th out of 425 stocks

TNGX stock logo

About Tango Therapeutics Stock (NASDAQ:TNGX)

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

TNGX Stock Price History

TNGX Stock News Headlines

Tango Therapeutics (NASDAQ:TNGX) Trading 5.1% Higher
Recap: Tango Therapeutics Q4 Earnings
TNGX Aug 2024 20.000 put
TNGX Mar 2024 7.500 call
TNGX Mar 2024 12.500 call
See More Headlines
Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
6/12/2024
Next Earnings (Estimated)
8/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TNGX
Fax
N/A
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.17
High Stock Price Target
$18.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+94.9%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-101,740,000.00
Net Margins
-299.88%
Pretax Margin
-299.41%

Debt

Sales & Book Value

Annual Sales
$36.53 million
Book Value
$2.48 per share

Miscellaneous

Free Float
100,222,000
Market Cap
$776.80 million
Optionable
Optionable
Beta
0.79
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Barbara L. Weber M.D. (Age 67)
    President, CEO & Director
    Comp: $1.04M
  • Dr. Adam S. Crystal M.D. (Age 47)
    Ph.D., President of Research & Development
    Comp: $977.22k
  • Dr. Alan Ashworth FRS (Age 63)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Dr. Levi Garraway M.D. (Age 55)
    Ph.D., Founder
  • Dr. William G. Kaelin Jr. (Age 66)
    M.D., Founder & Member of Scientific Advisory Board
  • Dr. Timothy K. Lu M.D. (Age 43)
    Ph.D., Founder
  • Dr. Antoni Ribas M.D. (Age 57)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. Timothy Redfern (Age 45)
    Chief Financial Officer
  • Mr. Jannik N. Andersen Ph.D.
    Chief Scientific Officer
  • Mr. Douglas J. Barry Esq. (Age 54)
    J.D., Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

TNGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Tango Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNGX shares.
View TNGX analyst ratings
or view top-rated stocks.

What is Tango Therapeutics' stock price target for 2024?

7 Wall Street analysts have issued 12 month price objectives for Tango Therapeutics' shares. Their TNGX share price targets range from $11.00 to $18.00. On average, they predict the company's share price to reach $14.17 in the next year. This suggests a possible upside of 104.7% from the stock's current price.
View analysts price targets for TNGX
or view top-rated stocks among Wall Street analysts.

How have TNGX shares performed in 2024?

Tango Therapeutics' stock was trading at $9.90 on January 1st, 2024. Since then, TNGX stock has decreased by 30.1% and is now trading at $6.92.
View the best growth stocks for 2024 here
.

When is Tango Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our TNGX earnings forecast
.

How were Tango Therapeutics' earnings last quarter?

Tango Therapeutics, Inc. (NASDAQ:TNGX) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.04. The company had revenue of $6.47 million for the quarter, compared to analysts' expectations of $7.13 million. Tango Therapeutics had a negative net margin of 299.88% and a negative trailing twelve-month return on equity of 44.35%.

Who are Tango Therapeutics' major shareholders?

Tango Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.89%), Artal Group S.A. (2.05%), Mass General Brigham Inc (0.33%), Affinity Asset Advisors LLC (0.14%), California State Teachers Retirement System (0.04%) and Susquehanna Fundamental Investments LLC (0.03%). Insiders that own company stock include Adam Crystal, Barbara Weber, Boxer Capital, Llc, Daniella Beckman, Douglas Barry, Mva Investors, Llc and Rock Ventures Iv LP Third.
View institutional ownership trends
.

How do I buy shares of Tango Therapeutics?

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TNGX) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners